GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Diclofenac Diethylamine (DDEA) gelOther: Placebo gel
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 47
- Registration Number
- NCT03497039
- Locations
- 🇬🇧
GSK Investigational Site, Leeds, United Kingdom
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
Not Applicable
Completed
- Conditions
- Xerostomia
- Interventions
- Other: WaterDevice: Biotene Original Oral RinseDevice: Biotene Moisturizing Mouth SprayDevice: Experimental Oralbalance Moisturizing Gel
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 422
- Registration Number
- NCT03494985
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
Phase 4
Completed
- Conditions
- Meningitis, Meningococcal
- Interventions
- Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)Biological: rMenB+OMV NZ vaccine
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1021
- Registration Number
- NCT03493919
- Locations
- 🇩🇪
GSK Investigational Site, Wuerzburg, Bayern, Germany
Daprodustat Bioequivalence and Food Effect Study
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT03493386
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
Phase 1
Completed
- Conditions
- Pain, Inflammatory
- Interventions
- Drug: GSK3858279 IVDrug: Placebo matching to GSK3858279 (SC or IV)Drug: GSK3858279 SCDrug: Placebo matching to GSK3858279 (SC)
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03485365
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: budesonide/formoterolDrug: albuterol/salbutamolDrug: FF/UMEC/VIDrug: Placebo to match budesonide/formoterolDrug: Placebo to match FF/UMEC/VIDrug: tiotropiumDrug: placebo to match tiotropiumDevice: ELLIPTADevice: MDIDevice: HandiHaler
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 729
- Registration Number
- NCT03478683
- Locations
- 🇳🇱
GSK Investigational Site, Zutphen, Netherlands
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo DPIDevice: ELLIPTA DPIOther: Ease of use questionnaires
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 222
- Registration Number
- NCT03478657
- Locations
- 🇨🇦
GSK Investigational Site, Windsor, Ontario, Canada
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: budesonide/formoterolDrug: albuterol/salbutamolDrug: FF/UMEC/VIDrug: Placebo to match budesonide/formoterolDrug: Placebo to match FF/UMEC/VIDrug: tiotropiumDrug: placebo to match tiotropiumDevice: ELLIPTADevice: MDIDevice: HandiHaler
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 732
- Registration Number
- NCT03478696
- Locations
- 🇩🇪
GSK Investigational Site, Leipzig, Germany
Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe
Not Applicable
Completed
- Conditions
- Denture Cleansers
- Interventions
- Other: Tap WaterDevice: Experimental Denture Wipe
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 152
- Registration Number
- NCT03478644
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FF/UMEC/VIDrug: TiotropiumDrug: Albuterol/salbutamolDrug: Placebo to match tiotropiumDrug: Placebo to match FF/UMEC/VIDevice: ELLIPTA inhalerDevice: HANDIHALERDevice: MDI
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 800
- Registration Number
- NCT03474081
- Locations
- 🇷🇺
GSK Investigational Site, Voronezh, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath